Nebenwirkungen · Zoely
Zoely 2.5 mg/1.5 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 13
HOS-123143 · Präparat HOS-095645
Six multi-centre clinical trials of up to one-year duration were used to evaluate safety of Zoely. In total 3,434 women, aged 18-50, were enrolled and completed 33,828 cycles. Most commonly reported adverse reactions in these clinical trials were acne (15.4%) and withdrawal bleeding irregular (9.8%). An increased risk for venous and arterial thromboembolism, causative of serious adverse events has been observed with the use of CHCs (see section 4.4)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-19T01:25:00Z · SHA-256 dc49cf8021f816c4c7a796f72b78aa51d7e7cdb416565d60506c315b6ddcb3e2 · Passage c6994d21106f08e08e98ad319799245242e97a001b907306c09a1ea8c46887ba · Zeichen 31–484 im Abschnitt